Abstract Library

#2766 Neuroendocrine Neoplasms Arising in Inflammatory Bowel Disease: Clinical Features of 69 Cases and Literature Review

Introduction: An increased prevalence of neuroendocrine neoplasms (NENs) has been reported in patients with inflammatory bowel disease (IBD). However, we know little about IBD complicating NENs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hu P, Bai J, Liu M, Tang Q,

Keywords: crohn’s disease, ulcerative colitis, neuroendocrine neoplasms, intestinal flora, immunity,

#2091 Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors

Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) are insufficient due to poor knowledge of these tumours. Despite showing differentiated features, NETs often exhibit therapeutic resistance to common treatments similarly to other cancers. Although signalling abnormalities have been reported, molecular mechanisms responsible for this resistance phenomenon are yet to be understood.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Romano D, Gerard C, Poizat F, Niccoli P, Barlier A,

Keywords: neuroendocrine tumors, drug resistance, proteomics, kinases, apoptosis,

#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures

Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Romano D

Authors: Mohamed A, Romano D, Poizat F, Delpero J, Niccoli P,

Keywords: pNETs primary culture, everolimus, somatostatin analogues, cell viability, chromogranin A secretion, Akt activity,

#961 Heterogeneity in the Ki-67 Index of Neuroendocrine Tumors

Introduction: Tumor heterogeneity due to tumor evolution is becoming more widely recognised. Neuroendocrine tumors (NET) are routinely graded using the Ki-67 index based on a single tumor location, however, this could lead to undergrading if the Ki-67 index is higher at the metastatic site.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Miller H, Flora R, Drymousis P, Wasan H, Goldin R,

Keywords: tumor heterogeneity, Ki-67,

#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia

Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Mosli Lynch C, Flora R, Hanna G, Nicholson A, Speller A,

Keywords: mixed adenoneuroendocrine carcinoma, MANEC, neuroendocrine tumors,